Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 3/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.44 |
| ▸ | HTR1A | P08908 | 3/20 | 0.43 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | VEGFA | P15692 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6289211 | 0.82 | SLC6A4 (0.48) | F10SLC6A4SLC6A2SLC6A3HTR1A | |
| SCHEMBL6414751 | 0.81 | SLC6A4 (0.47) | F10SLC6A4SLC6A2SLC6A3HTR1A | |
| SCHEMBL6289773 | 0.80 | SLC6A4 (0.49) | F10SLC6A4SLC6A2SLC6A3HTR1A | |
| SCHEMBL17609050 | 0.80 | VEGFA (0.46) | SLC6A4SLC6A2SLC6A3HTR1AMAPT | |
| SCHEMBL23010900 | 0.80 | SLC6A2 (0.43) | SLC6A4SLC6A2SLC6A3HTR1AMAPT | |
| SCHEMBL19317590 | 0.80 | SLC6A4 (0.40) | F10SLC6A4SLC6A2SLC6A3HTR1A | |
| SCHEMBL17624247 | 0.79 | SLC6A4 (0.46) | F10SLC6A4SLC6A2SLC6A3HTR1A | |
| SCHEMBL6290694 | 0.79 | SLC6A4 (0.46) | F10SLC6A4SLC6A2SLC6A3HTR1A | |
| SCHEMBL6289868 | 0.79 | SLC6A4 (0.48) | F10SLC6A4SLC6A2SLC6A3HTR1A | |
| SCHEMBL17623921 | 0.78 | SLC6A2 (0.58) | SLC6A4SLC6A2SLC6A3HTR1AMRGPRX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170253592-A1 | N-(HETERO)ARYL-SUBSTITUTED HETEROYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES OR CONDITIONS RELATED TO THE CENTRAL NERVOUS SYSTEM | SHIRE INTERNATIONAL GMBH (CH) | 2017-09-07 | — | — | US | disclosed |
| US-20170253615-A1 | Spirocyclic derivatives | SHIRE INTERNATIONAL GMBH (CH) | 2017-09-07 | — | — | US | disclosed |
| WO-2016042452-A1 | Spirocyclic derivatives | SHIRE INTERNATIONAL GMBH (CH) | 2016-03-24 | — | — | WO | disclosed |
| WO-2016042453-A1 | N-(HETERO)ARYL-SUBSTITUTED HETEROYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES OR CONDITIONS RELATED TO THE CENTRAL NERVOUS SYSTEM | SHIRE INTERNATIONAL GMBH (CH) | 2016-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253592-A1 | N-(HETERO)ARYL-SUBSTITUTED HETEROYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES OR CONDITIONS RELATED TO THE CENTRAL NERVOUS SYSTEM | SLC6A3, SLC6A2, SLC6A19 | F10 2422/4885SLC6A4 12/4885SLC6A2 2/4885 |
| US-20170253615-A1 | Spirocyclic derivatives | SLC6A3, SLC10A1, ABCB11 | F10 1004/4885SLC6A4 17/4885SLC6A2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.